A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.

Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P

The American journal of medicine1 May 1995Cited by 56 (Europe PMC)

PMID7733123DOI10.1016/s0002-9343(99)80344-1PepBankPUB-07733123

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In early postmenopausal women, combined salmon calcitonin groups had significantly better lumbar spine BMD evolution than placebo.
In plain wordsIn early postmenopausal women, spine bone density changed more favorably with combined salmon calcitonin groups than placebo.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD change versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 or 200 IU/day on 5 consecutive days per week · intranasalAs given in this study (human).
Measurements
P
0.0001
between groups
Source sentences
Summary
The difference between the evolution of the combined groups receiving nasal SCT and the group treated with the placebo was highly significant (P = 0.0001).
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design.
Summary · context
The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism.
Summary · context
They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83).
Summary · context
All treatments were given on 5 consecutive days per week.
Report a problemFND-0773312305
02HumanNon-randomized trialEfficacy outcome
In early postmenopausal women, lumbar spine BMD changed by 0.82% with salmon calcitonin, without significant change from baseline.
In plain wordsIn early postmenopausal women, spine bone density did not change significantly from baseline with salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeLumbar spine BMD, intention-to-treat
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 IU/day on 5 consecutive days per week · intranasalAs given in this study (human).
Measurements
BMD change
0.82%
IT
95% CI lower
−0.26%
IT
95% CI upper
1.89%
IT
Source sentences
Summary
LSBMD increased slightly with the 50-IU/d dose of SCT, by 0.82% (95% CI -0.26 to 1.89) in the IT population, and 0.51% (95% CI -0.69 to 1.72) in the VC (P = NS, versus baseline).
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design.
Summary · context
The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism.
Summary · context
They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83).
Summary · context
All treatments were given on 5 consecutive days per week.
Report a problemFND-0773312301
03HumanNon-randomized trialEfficacy outcome
In early postmenopausal women who completed treatment, lumbar spine BMD changed by 0.51% with salmon calcitonin, without significant change from baseline.
In plain wordsIn early postmenopausal completers, spine bone density did not change significantly from baseline with salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeLumbar spine BMD, valid completers
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 IU/day on 5 consecutive days per week · intranasalAs given in this study (human).
Measurements
BMD change
0.51%
VC
95% CI lower
−0.69%
VC
95% CI upper
1.72%
VC
Source sentences
Summary
LSBMD increased slightly with the 50-IU/d dose of SCT, by 0.82% (95% CI -0.26 to 1.89) in the IT population, and 0.51% (95% CI -0.69 to 1.72) in the VC (P = NS, versus baseline).
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design.
Summary · context
The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism.
Summary · context
They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83).
Summary · context
All treatments were given on 5 consecutive days per week.
Report a problemFND-0773312302
04HumanNon-randomized trialEfficacy outcome
In early postmenopausal women, salmon calcitonin increased lumbar spine BMD by 2.03% from baseline in the intention-to-treat population.
In plain wordsIn early postmenopausal women, salmon calcitonin increased spine bone density from baseline.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD, intention-to-treat
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day on 5 consecutive days per week · intranasalAs given in this study (human).
Measurements
BMD change
2.03%
IT
95% CI lower
0.92%
IT
95% CI upper
3.15%
IT
P
0.001
IT
Source sentences
Summary
Subjects who received SCT 200 IU/d experienced significant increases of 2.03% (95% CI 0.92 to 3.15) in the IT population and 2.26% (95% CI 1.01 to 3.51) in the VC (both P = 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design.
Summary · context
The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism.
Summary · context
They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83).
Summary · context
All treatments were given on 5 consecutive days per week.
Report a problemFND-0773312303
05HumanNon-randomized trialEfficacy outcome
In early postmenopausal completers, salmon calcitonin increased lumbar spine BMD by 2.26% from baseline.
In plain wordsIn early postmenopausal completers, salmon calcitonin increased spine bone density from baseline.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD, valid completers
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day on 5 consecutive days per week · intranasalAs given in this study (human).
Measurements
BMD change
2.26%
VC
95% CI lower
1.01%
VC
95% CI upper
3.51%
VC
P
0.001
VC
Source sentences
Summary
Subjects who received SCT 200 IU/d experienced significant increases of 2.03% (95% CI 0.92 to 3.15) in the IT population and 2.26% (95% CI 1.01 to 3.51) in the VC (both P = 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design.
Summary · context
The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism.
Summary · context
They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83).
Summary · context
All treatments were given on 5 consecutive days per week.
Report a problemFND-0773312304
06HumanNon-randomized trialEfficacy outcome
In early postmenopausal women, biochemical bone turnover parameters showed no significant changes during the study.
In plain wordsIn early postmenopausal women, biochemical measures of bone turnover did not change significantly during the study.
Peptide
Calcitonin-salmon
Outcome
No significant changeBiochemical bone turnover parameters
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 or 200 IU/day on 5 consecutive days per week · intranasalAs given in this study (human).
Source sentences
Summary
No significant changes were recorded in biochemical parameters reflecting bone turnover.
5 context sentences(design, population, supporting numbers)
Summary · context
The main assessments performed were bone mineral density of the lumbar spine (LSBMD) and biochemical parameters reflecting bone turnover (serum alkaline phosphatase, urinary calcium/creatinine, and hydroxyproline/creatinine ratios).
Summary · context
We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design.
Summary · context
The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism.
Summary · context
They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83).
Summary · context
All treatments were given on 5 consecutive days per week.
Report a problemFND-0773312306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.